Literature DB >> 22739938

MiR-138 suppressed nasopharyngeal carcinoma growth and tumorigenesis by targeting the CCND1 oncogene.

Xia Liu1, Xiao-Bin Lv, Xiao-Pai Wang, Yi Sang, Shuangbing Xu, Kaishun Hu, Mansi Wu, Yi Liang, Pan Liu, Jianjun Tang, Wen-Hua Lu, Qi-Sheng Feng, Li-Zhen Chen, Chao-Nan Qian, Jin-Xin Bei, Tiebang Kang, Yi-Xin Zeng.   

Abstract

The microRNA miR-138 is dysregulated in several human cancers, but the underlying mechanism remains largely unknown. Here, we report that miR-138 is commonly underexpressed in nasopharyngeal carcinoma (NPC) specimens and NPC cell lines. The ectopic expression of miR-138 dramatically suppressed cell proliferation and colony formation in vitro and inhibited tumorigenesis in vivo. Moreover, we identified the cyclin D1 (CCND1) gene as a novel direct target of miR-138. In consistent with the knocked-down expression of CCND1, overexpression of miR-138 inhibited cell growth and cell cycle progression in NPC cells. Furthermore, CCND1 was widely upregulated in NPC tumors, and its mRNA levels were inversely correlated with miR-138 expression. Taken together, our findings suggest that miR-138 might be a tumor suppressor in NPC, which is exerted partially by inhibiting CCND1 expression. The identification of functional miR-138 in NPC and its direct link to CCND1 might provide good candidates for developing diagnostic markers and therapeutic applications for NPC.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22739938     DOI: 10.4161/cc.20898

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  54 in total

1.  miR-138-Mediated Regulation of KINDLIN-2 Expression Modulates Sensitivity to Chemotherapeutics.

Authors:  Khalid Sossey-Alaoui; Edward F Plow
Journal:  Mol Cancer Res       Date:  2015-10-16       Impact factor: 5.852

2.  Upregulation of Neutrophil Gelatinase-Associated Lipocalin in Colorectal Cancer Predicts Poor Patient Survival: Reply.

Authors:  Herbert Maier; Felix Aigner
Journal:  World J Surg       Date:  2016-04       Impact factor: 3.352

3.  MicroRNA-138 and SIRT1 form a mutual negative feedback loop to regulate mammalian axon regeneration.

Authors:  Chang-Mei Liu; Rui-Ying Wang; Zhong-Xian Jiao; Bo-Yin Zhang; Feng-Quan Zhou
Journal:  Genes Dev       Date:  2013-06-24       Impact factor: 11.361

4.  Prognostic potential of microRNA-138 and its target mRNA PDK1 in sera for patients with non-small cell lung cancer.

Authors:  Lihong Han; Guoxiu Zhang; Nali Zhang; Haiyan Li; Yanyan Liu; Aiguo Fu; Youguang Zheng
Journal:  Med Oncol       Date:  2014-07-27       Impact factor: 3.064

5.  Molecular classification and molecular targeted therapy of cancer.

Authors:  Miao Xu; Jianyong Shao; Yixin Zeng
Journal:  Front Med       Date:  2013-06       Impact factor: 4.592

6.  Gene expression of miRNA-138 and cyclin D1 in oral lichen planus.

Authors:  Noha A Ghallab; Rehab Fawzy Kasem; Safa Fathy Abd El-Ghani; Olfat G Shaker
Journal:  Clin Oral Investig       Date:  2017-03-08       Impact factor: 3.573

7.  Role of microRNA-4458 in patients with non-small-cell lung cancer.

Authors:  Lidao Bao; Linlin Wang; Guomin Wei; Yuehong Wang; Gerile Wuyun; Agula Bo
Journal:  Oncol Lett       Date:  2016-09-22       Impact factor: 2.967

8.  MiR-26a and miR-138 block the G1/S transition by targeting the cell cycle regulating network in prostate cancer cells.

Authors:  Kati Erdmann; Knut Kaulke; Christiane Rieger; Karsten Salomo; Manfred P Wirth; Susanne Fuessel
Journal:  J Cancer Res Clin Oncol       Date:  2016-08-25       Impact factor: 4.553

9.  Role of miR-138 in the regulation of larynx carcinoma cell metastases.

Authors:  Shang Gao; Jie Wang; Jin Xie; Tianzhen Zhang; Pin Dong
Journal:  Tumour Biol       Date:  2015-10-24

Review 10.  Role of microRNA-138 as a potential tumor suppressor in head and neck squamous cell carcinoma.

Authors:  Yi Jin; Dan Chen; Robert J Cabay; Anxun Wang; David L Crowe; Xiaofeng Zhou
Journal:  Int Rev Cell Mol Biol       Date:  2013       Impact factor: 6.813

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.